Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery
This study is currently recruiting participants.
Verified by Maimonides Medical Center, September 2007
Sponsored by: Maimonides Medical Center
Information provided by: Maimonides Medical Center
ClinicalTrials.gov Identifier: NCT00533845
  Purpose

After Laparoscopic surgery most patients experience some form of mild to moderate pain. The current standard of care is to treat this pain with local anesthetics (numbing medication, that deadens the nerve endings) to the small surgical incisions (cuts) and narcotic systemic analgesics (medication injected into your vein to control pain such as morphine).

Although this treatment improves pain symptoms it is not perfect. Firstly, complete pain control is rarely achieved and secondly, narcotics (such as morphine) often have many side effects including nausea, vomiting, sedation (sleepiness), constipation and abdominal upset. All of these issues make recovery less comfortable and delays return to full function (work, school and other activities of daily life).

A new FDA approved device is now available that offers the benefits of long term anesthesia without the side effects of narcotics. It consists of a pump that continuously infuses local anesthesia into and around the surgical site. This pump is placed during your operation. You then carry a tennis ball sized container made of soft plastic in a pouch which drips numbing medicine around your wounds for 2 days continuously.

The purpose of this study is to see if this pump improves postoperative pain, decreases the need for narcotic pain medicine and allows people to return to their activities earlier.


Condition Intervention
Postoperative Pain
Device: On-Q Pain Pump

MedlinePlus related topics: Nausea and Vomiting
Drug Information available for: Bupivacaine Bupivacaine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Further study details as provided by Maimonides Medical Center:

Primary Outcome Measures:
  • Pain assessment using a subjective pain visual analog scale VAS, evaluation of narcotic requirements, presence of nausea and vomiting, and all side effects relatable to bupivicaine administration. [ Time Frame: 48 hours postop ]

Study Start Date: September 2007
Estimated Study Completion Date: September 2008
Intervention Details:
    Device: On-Q Pain Pump
    Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
Detailed Description:

The procedure of the current study is to randomly assign patients undergoing minimally invasive surgeries (laparoscopic cholecystectomies and laparoscopic Lap-Banding procedures) to one of two groups. Both groups will have the standard surgical procedure performed and then at the completion will have the on-Q system placed in a subdiaphragmatic (within the abdomen) location. Half of the study group will have bupivicaine, a numbing medicine in the pump while the other half will have sterile saline in their pump. Neither the patient nor the surgeon will be aware of which group any particular patient is in, this is a process known as "blinding" and improves the reliability of the results. All patients will receive the standard locally infiltrated trocar site local anesthetic and either a prescription for Vicodin for ambulatory patients or morphine injected into their vein for patients staying in the hospital.

All patients will then be asked at preset intervals their level of pain the presence of nausea and their need for Vicodin or morphine. Ambulatory patients will be reached by phone for answers to these questions. All patients will have their pain controlled in the usual and standard way at all times. The On-Q pump will be removed at 48hours.

The results will then be statistically reviewed to see if the On-Q pumps were of benefit.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing laparoscopic cholecystectomy or Lap-Band ASA III or less

Exclusion Criteria:

  • Patients who refuse consent
  • Are converted from laparoscopy to open surgery
  • Are allergic to bupivacaine
  • Are unable to followup
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00533845

Contacts
Contact: Danny A Sherwinter, MD 7182837952 Dsherwinter@maimonidesmed.org

Locations
United States, New York
Maimonides Medical Center Recruiting
Brooklyn, New York, United States, 11219
Sponsors and Collaborators
Maimonides Medical Center
Investigators
Principal Investigator: Danny A Sherwinter, MD Maimonides Medical Center
  More Information

Study ID Numbers: 07/04/IVA4
Study First Received: September 20, 2007
Last Updated: November 16, 2007
ClinicalTrials.gov Identifier: NCT00533845  
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Signs and Symptoms
Postoperative Complications
Bupivacaine
Pain
Pain, Postoperative

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on January 16, 2009